Skip to main content

Aquestive Therapeutics, Inc.

corporate_fare Company Profile

Aquestive Therapeutics, Inc.

AQST·NASDAQ·Life Sciences·CIK 0001398733

Aquestive is a pharmaceutical company focused on developing medicines using innovative science and delivery technologies. The company aims to provide alternatives to invasive standard-of-care therapies by delivering complex molecules through non-invasive administrations. Aquestive is advancing Anaphylm™, a late-stage non-device based epinephrine prodrug product candidate for severe allergic reactions, including anaphylaxis, and its AdrenaVerse™ epinephrine prodrug pipeline platform. Aquestive has four licensed commercialized products, which are marketed globally by its licensees. The company is the exclusive manufacturer of these licensed products. Aquestive also collaborates with other pharmaceutical companies, utilizing proprietary technologies such as PharmFilm®, and possesses drug development and commercialization capabilities. The company's production facilities are located in Portage, Indiana, while its corporate headquarters and primary research laboratory facilities are in Warren, New Jersey. Aquestive manufactures licensed products at its facilities and anticipates its current manufacturing capacity is sufficient for commercial quantities of its licensed products and proprietary product candidates in development. Its facilities have been inspected by the FDA, TGA, and DEA, and are subject to inspection by other health agencies, including ANVISA and EMA. Aquestive is a worldwide leader in oral film drug delivery and manufacturing, having historically supplied the substantial majority of the world's oral films for prescription pharmaceutical use and shipped over two billion doses globally. Its PharmFilm® technology uses proprietary polymer compositions as film formers for active pharmaceutical ingredients (APIs) and excipients.

Aquestive Therapeutics, Inc. (NASDAQ:AQST) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for AQST at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for AQST spans 8-K, 10-Q, DEF 14A, 10-K.

Recent high-impact activity:

  • Aquestive Investor Deck Details $95M Contingent Funding Access Ahead of March 2027 Anaphylm PDUFA
  • Aquestive 10-Q: Cash Falls to $90.3M, Stockholders' Deficit Widens to $70.8M
  • Aquestive Q3 Revenue Falls 41% to $7.6M; Anaphylm PDUFA Set for March 16, 2027
  • Q3 Revenue Drops 41% to $7.6M as Net Loss Widens
  • FDA Accepts Anaphylm NDA Resubmission, Sets March 16, 2027 Decision Date

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$44.55M
Net Income
-$83.78M
Diluted EPS
-$0.78
Op. Cash Flow
-$52.43M
Free Cash Flow
-$52.99M
Gross Profit
$25.99M
Operating Income
-$71.05M
Cash & Equivalents
$121.17M
Debt / Equity
0.00×
Net Margin
-188.1%
Shares Outstanding
122.04M sh
Source: 10-K · filed 2026-03-04 · accession 0001398733-26-000018

Short Interest & Short Volume

13.24 days to cover

FINRA reported short interest of 29,318,686 shares in AQST as of the October 30, 2026 settlement, a 6.2% increase from the prior period — about 13.2 days to cover at its recent average daily volume. On November 20, 2026, 67.8% of AQST volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)29,318,686 shares as of October 30, 2026
Change vs prior period▲ 6.2%
Days to cover13.24 at avg daily volume of 2,214,429
Daily short volume (FINRA facilities)67.8% of 1,692,865 shares on November 20, 2026
5-day average short volume59.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for AQST, detected from its recent SEC filings.

1 shelf registration

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$3.52 +1.73% today
52-week range · as of 2026-11-05 $2.93 – $6.85
Market cap
$434.88M
Volume
3.4M (1.3× avg)
3-mo avg 2.5M
Live data · 2026-11-22 04:01 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed AQST - Latest Insights

AQST
Nov 05, 2026, 4:17 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.66
Real-time Price: $3.52 info
Change: -$0.140 (-4%) info
Market Cap: $434.879M info
AQST
Nov 03, 2026, 4:19 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.80
Real-time Price: $3.52 info
Change: -$0.280 (-7%) info
Market Cap: $434.879M info
AQST
Nov 03, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.69
Real-time Price: $3.52 info
Change: -$0.170 (-5%) info
Market Cap: $434.879M info
AQST
Nov 03, 2026, 4:01 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $3.61
Real-time Price: $3.52 info
Change: -$0.0901 (-2%) info
Market Cap: $434.879M info
AQST
Oct 15, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Updated Oct 15, 7:22 AM ET — The FDA classified the Anaphylm NDA resubmission as a Class 2 response, and Aquestive remains on track to file a Canadian New Drug Submissi…
Price at Filing: $4.58
Real-time Price: $3.52 info
Change: -$1.06 (-23%) info
Market Cap: $434.879M info
AQST
Oct 14, 2026, 7:21 AM EDT
Filing Type: 8-K
Importance Score:
8
Updated Oct 14, 8:07 AM ET — Eton expects to launch Libervant next year, subject to final FDA approval.
Price at Filing: $4.79
Real-time Price: $3.52 info
Change: -$1.27 (-27%) info
Market Cap: $434.879M info
AQST
Sep 17, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.90
Real-time Price: $3.52 info
Change: -$1.38 (-28%) info
Market Cap: $434.879M info
AQST
Sep 17, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.00
Real-time Price: $3.52 info
Change: -$1.48 (-30%) info
Market Cap: $434.879M info
AQST
Aug 11, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.35
Real-time Price: $3.52 info
Change: -$0.830 (-19%) info
Market Cap: $434.879M info
AQST
Aug 11, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.22
Real-time Price: $3.52 info
Change: -$0.700 (-17%) info
Market Cap: $434.879M info
AQST
Aug 10, 2026, 2:06 PM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $4.46
Real-time Price: $3.52 info
Change: -$0.935 (-21%) info
Market Cap: $434.879M info
AQST
Aug 10, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.01
Real-time Price: $3.52 info
Change: -$0.490 (-12%) info
Market Cap: $434.879M info
AQST
May 13, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.75
Real-time Price: $3.52 info
Change: -$1.23 (-26%) info
Market Cap: $434.879M info
AQST
May 13, 2026, 4:04 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.84
Real-time Price: $3.52 info
Change: -$1.32 (-27%) info
Market Cap: $434.879M info
AQST
May 13, 2026, 4:01 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $4.32
Real-time Price: $3.52 info
Change: -$0.800 (-19%) info
Market Cap: $434.879M info
AQST
Apr 24, 2026, 5:00 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $4.06
Real-time Price: $3.52 info
Change: -$0.5412 (-13%) info
Market Cap: $434.879M info
AQST
Mar 30, 2026, 7:44 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.05
Real-time Price: $3.52 info
Change: -$0.530 (-13%) info
Market Cap: $434.879M info
AQST
Mar 20, 2026, 7:36 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.92
Real-time Price: $3.52 info
Change: -$0.400 (-10%) info
Market Cap: $434.879M info
AQST
Mar 05, 2026, 3:03 PM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $4.30
Real-time Price: $3.52 info
Change: -$0.775 (-18%) info
Market Cap: $434.879M info
AQST
Mar 04, 2026, 4:21 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $4.15
Real-time Price: $3.52 info
Change: -$0.630 (-15%) info
Market Cap: $434.879M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets